PRIMARY OBJECTIVE:~• To determine the efficacy (overall response rate) and safety profile of the Pirtobrutinib plus venetoclax combination in relapsed refractory MCL patients~SECONDARY OBJECTIVE:~• To evaluate the survival (including overall and progression-free survival) of the Pirtobrutinib plus venetoclax combination in relapsed refractory MCL patients.~EXPLORATORY STUDIES:~•Exploratory studies are planned on the trial and the final analysis and methodology including bio-informatics analysis
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).